3SBio (HKG:1530) and subsidiary Shenyang Sunshine Pharmaceutical will grant Pfizer an exclusive license to develop, manufacture, and commercialize its PD-1/VEGF injection for cancer worldwide excluding mainland China.
Under the agreement, Pfizer will shoulder development and regulatory costs for future trials of the drug, the filing said.
3SBio will be eligible to receive $1.25 billion in upfront payments and could receive up to $4.80 billion in development, regulatory approval and sales milestone payments.
The SSGJ-707 drug is about to undergo phase 3 trials in China for programmed death-ligand 1-positive locally advanced or metastatic non-small cell lung cancer, according to a Tuesday filing with the Hong Kong bourse.
It is also undergoing several phase 2 studies for the combination of the drug with chemotherapy for the first-line treatment of advanced non-small cell lung cancer, metastatic colorectal cancer, and advanced gynecological tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。